The long term management of COPD has been affected by the latest “me-too” drug to be announced.  Until now the only long-acting anti-muscarinic drug available was tioptropium. Until now, Boehringer-Ingelheim have had this important field to themselves.  But now, Almirall … Continue reading

Generally speaking, it is always preferable to opt for the fewest possible doses of a long-term medication a day.  Adherence is improved. So the introduction by Novartis of a new once a day long-acting beta-adrenoceptor agonist for people with chronic … Continue reading